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Background: Arterial thrombosis triggered by vascular injury is a balance between thrombus growth and thrombus
fragmentation (dethrombosis). Unbalance towards thrombus growth can lead to vascular occlusion, downstream
ischemia and tissue damage.
Here we describe the development of a simple methodology that allows for continuous real time monitoring and
quantification of both processes during perfusion of human blood under arterial shear rate conditions. Using this
methodology, we have studied the effects of antiplatelet agents targeting COX-1 (aspirin), P2Y12 (2-MeSAMP,
clopidogrel), GP IIb-IIIa (eptifibatide) and their combinations on the kinetics of thrombosis over time.
Results: Untreated samples of blood perfused over type III collagen at arterial rates of shear promoted the growth
of stable thrombi. Modulation by eptifibatide affected thrombus growth, while that mediated by 2-MeSAMP and
aspirin affected thrombus stability. Using this technique, we confirmed the primacy of continuous signaling by the
ADP autocrine loop acting on P2Y12 in the maintenance of thrombus stability. Analysis of the kinetics of thrombosis
revealed that continuous and prolonged analysis of thrombosis is required to capture the role of platelet signaling
pathways in their entirety. Furthermore, studies evaluating the thrombotic profiles of 20 healthy volunteers treated
with aspirin, clopidogrel or their combination indicated that while three individuals did not benefits from either
aspirin or clopidogrel treatments, all individuals displayed marked destabilization profiles when treated with the
combination regimen.
Conclusions: These results show the utility of a simple perfusion chamber technology to assess in real time the
activity of antiplatelet drugs and their combinations. It offers the opportunity to perform pharmacodynamic
monitoring of arterial thrombosis in clinical trials and to investigate novel strategies directed at inhibiting thrombus
stability in the management of cardiovascular disease.
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It is recognized that formation of arterial thrombi
(thrombus growth) depends on platelet activation, result-
ing in the activation of the receptor function of GP IIb-
IIIa for fibrinogen and von Willebrand factor to mediate
platelet aggregation. Under shear stress conditions such
as those found in stenosed arteries, platelet activation
triggered by either von Willebrand factor interactions
with GP Ibα and GP IIb-IIIa [1–4], GP VI binding to col-
lagen [5], or ADP and TxA2 binding to their respective
receptors (P2Y12, TP) [6] have been shown to mediate
thrombus growth. Unlike for the effectors of thrombus
growth, our knowledge of the effectors of dethrombosis
is limited, in part due to a lack of appropriate technology.
It is known that fibrin stabilizes platelet-rich arterial
thrombi (accounting for the ability of fibrinolytics to en-
hance vessel patency [7]) and that inhibition of GP IIb-
IIIa also has some efficacy in reversing arterial thrombi
[8]. Models utilizing intravital microscopy have opened a
new era as they permitted real-time analysis of the kinet-
ics of thrombosis and helped discover multiple secondary
mediators of thrombus growth and stability (reviewed in
[9]). In light of the significant discoveries associated with
the use of live microscopy, some laboratories have
decided to couple the features of intravital microscopy
with perfusion chamber technology to better understand
the kinetics of human thrombosis under flow. As a result,
it was demonstrated that continuous ADP-P2Y12 signal-
ing is critical for maintaining the active conformation
level of GP IIb-IIIa to promote thrombus stability
[10,11]. This observation, however, required specialized
laboratories with expensive best-in-class technology.
Since drugs used to treat arterial thrombosis are
believed to affect key mediators of thrombus growth
and/or stability we decided to develop a simple perfu-
sion chamber assay that allows for mechanistic studies
but also continuous monitoring of the pharmacody-
namic activity of antiplatelet agents on the kinetics of
thrombosis in real time.
Results and discussion
The thrombosis profiler (Additional file 1: Figure S1A)
consisted of a custom built epifluorescence microscope,
a syringe pump and a holding stage (Additional file 1:
Figure S1B) in which sits a glass capillary (Vitrocom,
0.2 mm x 2 mm section) coated with human type III fi-
brillar collagen [12]. In a first set of experiments, we
analyzed the homogeneity of the collagen coating. To do
so, thrombotic deposits were rinsed for 40 seconds by
perfusion of a rinsing buffer, followed by perfusion of a
phosphate buffer solution (used for collagen dialysis)
supplemented with glutaraldehyde (final concentration
of 2.5%). Fixation was continued for another 2 hours.
Post-fixation with KMnO4, dehydration in ethanol wasfollowed by epon embedding, removal of the glass sur-
face and a second embedding in epon. Evaluation of the
thrombotic deposits was performed on semi-thin cross-
section cut perpendicular to the direction of the blood
flow at the proximal part of the capillary [12]. En Face
examination indicated homogenous distribution in size
and location of platelet-rich thrombi (Additional file 1:
Figure S1C). We next analyzed rhodamine 6 G uptake
by platelets in whole blood. Immediately after collection,
blood was labeled with rhodamine-6 G (1.25 μg/mL)
and maintained at 37°C for the entire course of the ex-
periment. In 10-minute intervals, 5 μL of blood was
sampled and diluted into 1.4 mL of sheath fluid buffer
(BD, San Jose, CA). Two minutes after the dilution, each
sample was analyzed by BD FACSCalibur. The forward
scatter (FSC), side scatter (SSC), and fluorescence chan-
nel (FL1) were set at logarithmic scale. A total of 10,000
events in the platelet region were collected. The geomet-
ric mean fluorescence of platelets was measured with
FL1 gain set at 999 (to allow detection of rhodamine
6 G). A total of 5 different samples were analyzed. Data
indicated that constant fluorescence of the platelets is
achieved after 20 minutes and lasted for at least 70 min-
utes (Additional file 1: Figure S1D).
Software development for quantification of platelet
deposition
Segmentation, partitioning of an image into non-
overlapping regions, was accomplished based on a method
proposed by Otsu [13]. This algorithm locates a point in
the histogram to minimize the intra-class variance of the
foreground and the background. Once the threshold is
determined, pixels with values lower than the threshold (e.
g., circulating blood) are classified as background and pix-
els with values greater than the threshold (e.g., platelets
and thrombi) are marked as foreground. The success of
this thresholding method centers upon whether the
proper threshold exists and whether it can be inferred
from the image histogram. If, for example, the surface re-
flectance of the objects to be segmented is not distinct
from the background or if the scene is not evenly illumi-
nated then the resulting image histogram would not pro-
duce a bimodal or multi-modal graph to allow the
computation of best possible threshold. For this reason we
adopted a multi-stage segmentation process. Thus after
applying the threshold to generate a binary image, mor-
phological operation “closing” (dilation followed by
erosion-used to fill in holes and small gaps) followed by
morphological operation “opening” (erosion followed by a
dilation-used to eliminate all pixels in regions that are too
small to contain the structuring element) is applied to join
together the thrombi objects and clear the image of small
artifacts. Next, a median filter was applied to further re-
duce the salt-and-pepper noise while simultaneously
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flowing whole blood that was perfused during the first 20
seconds was used for threshold determination, expressed
as background object and not taken into consideration in
the calculation of the mean fluorescence intensity. Lastly,
a watershed algorithm [14] was applied to identify individ-
ual thrombi in the image. Once the image was segmented,
the sum of intensity values of pixels inside each fore-
ground object was divided by the corresponding object
area (μm2) for every frame (sec). Other parameters
recorded were the time to reach the peak (sec) and the
slope before and after the peak (Additional file 1: Figures
S1E, S1F). Similar technology and software analysis can be
used for evaluation of the pro-coagulant activity of plate-
lets under flow (data not shown).
Assay validation
In initial experiments, we established the thrombotic
profiles of untreated samples of blood at different wall
shear rates (from 125/sec to 2000/sec) by varying the
flow rate fixed by the pump (Figure 1A). We then deter-
mined the window of experimentation. Six differentFigure 1 A), Examples of thrombotic profiles generated by the perfus
healthy individual on fibrillar collagen at different shear rates (repres
wall shear rate increases. At least three main factors may contribute to the
increase amount of platelets in the vicinity of the collagen surface, ii) a par
higher wall shear rate conditions, iii) an exponential increase in shear rate a
profiles could be also observed at lower wall shear rates but for longer per
blood perfused at 1000/sec, 15, 30, 45, 60 75 and 90 minutes post blood c
blood collection is plotted as mean + S.E.M for Peak thrombus size in C ancollagen-coated capillaries were utilized per individual to
determine whether the thrombotic profiles (generated at
1000/sec) varied according to the length of time post
blood collection (Figure 1B). Data were generated by
perfusing whole blood from 6 individuals at 15, 30, 45,
60, 75, and 90 minutes post blood collection. Untreated
samples of blood demonstrated identical profiles be-
tween T30 and T90 minutes post-blood draw (Table 1;
Figure 1B-D; Additional file 2: Video S1). Figure 2C
and D demonstrate that neither the maximum peak (C)
nor slope before the peak (D) were significantly differ-
ent at any of the time points measured beyond T15
minutes. The smaller flurorescence detected at the
15 min time-point is likely related to sub-optimal stain-
ing (see Additional file 1: Figure S1D). As a result, the
window of experimentation was determined to be be-
tween 30 and 90 minutes post blood collection.
Assay reproducibility
Within donor variability was established by perfusing 3
whole blood samples collected on different days from 6
individuals at 1000/sec. Maximum peak and slope wereion of untreated FXa-anticoagulated samples of blood from a
entative of 5 different donors). The profiles lose their linearity as the
exponential curve observed for wall shear rates > 500/sec. i) an
ticipation of von Willebrand factor in the thrombotic deposits for
t the apex of the thrombi. As a result, it is expected that exponential
fusion period. B), Representative thrombotic profiles of untreated
ollection from a single individual. The working range of the assay post
d slope before peak in D.
Table 1 Within donor variability of Peak Fluorescence (Pixels/Total Area (μm2)) and Slope (sBP-Arbitrary Units) of
thrombotic profile assessed by RTTP
Donor Peak thrombosis (t = 300 sec) Slope (sBP)
Assay 1 Assay 2 Assay 3 Mean SD *CV Assay 1 Assay 2 Assay 3 Mean SD *CV
1 304 426 346 359 62 0.17 1.08 1.58 1.29 1.32 0.25 0.19
2 887 945 1140 991 132 0.13 3.52 3.45 4.37 3.78 0.51 0.13
3 597 616. 447 554 92 0.17 2.14 2.28 1.73 2.05 0.29 0.14
4 1067 1162 956 1062 103 0.10 4.52 4.62 4.69 4.61 0.08 0.02
5 443 393 463 433 36 0.08 1.89 1.69 1.79 1.79 0.10 0.05
6 904 1024 942 957 61 0.06 3.74 4.59 3.85 4.06 0.47 0.11
The coefficient of variation (CV) was determined by measurement of peak thrombus size (P) and slope of thrombotic process (sBP) for 3 different samples taken
from 6 individuals. * CV = (SD/mean).
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cient of variation for each individual was calculated as
SD/mean, ranging from 0.06 to 0.17 in maximum peak
and from 0.02-0.19 in slope before peak.Figure 2 Representation of the mean ± S.E.M. of the thrombotic prof
MeSAMP (10, 100 μM) and eptifibatide (2.4 μM) in absence or presen
(eptifibatide (μM) spiked in vitro) inhibits thrombus growth. A monolayer o
Effects of 2-MeSAMP on thrombus formation. C), Effects of 2-MeSAMP on t
D), representative photomicropgraphs of the thrombotic deposits.Characterization of the kinetics of thrombosis
Thrombosis triggered by type III collagen followed the clas-
sical pattern described by the group of K.S. Sakariassen : i)
an increase in thrombus size that parallels that of the walliles of the blood of 7 individuals treated in vitro with saline, 2-
ce of aspirin (325 mg/d for 3 days). A), GP IIb-IIIa antagonism
f platelets is found at the highest dose of eptifibatide (2.4 μM). B),
hrombus formation on an aspirin background (325 mg/d for 3 days).
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thrombi gradually decreased in size towards the distal part
(data not shown). The continuous monitoring revealed a
linear increase in thrombus growth for lower wall shear
rates (125 to 750/sec), a profile that progressively becomes
exponential for higher levels of shear. Similar findings
were reported by the group of Dr. McIntire on a collagen
type I-vWf-coated surface [16].Antithrombotic activities of antiplatelet agents
Eptifibatide, inhibited thrombus growth independently
of the shear rates (data not shown), and inhibited
thrombus growth in a dose-dependent manner at 1000/
sec, reaching a maximal effect at 2.4 μM (Figure 2A).
Previously, we found that genetic targeting of P2Y12
promoted a cyclic thrombotic process in injured mesen-
teric arteries in mice [17]. We investigated how antag-
onism of the P2Y12 receptor would affect human
thrombosis. Addition of 2-MeSAMP at 100 μM (a dose
that fully inhibits platelet aggregation triggered by
10 μM ADP [12]) did not affect the initial growth of
thrombi on collagen but allowed for cyclic thrombotic
process characterized by the continuous formation and
embolization of small platelet thrombi in the absence of
occlusion (Figure 2B; Additional file 3: Video S2). Low
antagonism of P2Y12 by 2-MeSAMP (10 μM) in pres-
ence of aspirin recapitulated the profile obtained with
full P2Y12 antagonism, consisting in the formation and
embolization of platelet-rich thrombi (Figure 2C, D;
table 2 and Additional file 4: Video S3). Since some
individuals developed small, while others developed lar-
ger thrombi upon pre-treatment with the antiplatelet
agents, the time to embolization varies. Accordingly,
the mean curve of the different profiles appeared
flat. The formation and size of emboli was depicted
by the extent of the SEM (for example, see Figure 3D
and the curves comparing aspirin alone and




























0/7# 2/7# −0.3 ± 0.1 4/7# −0.5 ± 0.24 1/7
Compounds were added to untreated or aspirinated blood samples (individuals on
baseline, respectively. †, ††, P < 0.05, P < 0.01 vs aspirin (n = 7). # indicates number oThe importance of capturing the kinetics of throm-
bosis was further highlighted in Figure 3A-D. Data
showed that the antithrombotic activity (both qualitative
and quantitative) of the different compounds and their
combination varied according to the duration of the
blood perfusion and the process (growth or stability)
they affect. All capillaries perfused with untreated sam-
ples of blood occluded before 500 sec. While aspirin did
not show activity at 150 sec, its curve reached a plateau
beyond 200 sec. The combination of aspirin with
PRT060128 showed stronger antithrombotic activity,
reaching an inflexion point after 150 sec. The size of the
error bars (sem smaller for the combination of drugs
than for aspirin alone) indicated a constant formation
and embolization of smaller thrombi (Figure 3C, D).
Eptifibatide (0.5 μM, the concentration achieved during
the IMPACT-II trial) only affected thrombus growth and
could not prevent occlusion in 2 out of the 5 capillaries
over the 500 sec period (although the Figure 3A sug-
gested strong activity), indicating ability to delay but not
to prevent vascular occlusion. This is in sharp contrast
with the interpretation of the Figure 3A that suggested
that eptifibatide (0.5 μM) displayed ~ 50% inhibition
while aspirin was ineffective. Greater concentration of
eptifibatide (2.4 μM) abolished the thrombotic process
throughout the entire duration of the experiment
(Figure 3D).Constant signaling via P2Y12 is critical for thrombus
stability
Since stabilization of arterial thrombi is a function of
intraplatelet signaling pathways and is directly affected
by the thrombus size and the flow conditions, times to
embolization can vary between individuals. By conse-
quence, “flat” thrombotic profiles (see Figures 2B, 3D)
are plotted when the mean of multiple experiments is
computed and the notion of thrombus stability is repre-









± 61 423 218± 530 **,† 189 127 ± 33 ***, †† 103 63.5 ± 12 *** 53
+ 0.5 239 214± 12 228 204.6 ± 16 *,†† 233 234.4 ± 10 240
+ 0.37 2.14 1.33 ± 0.4 **,† 1.13 0.77 ± 0.2 ***,†† 0.43 0.34 ± 0.07 *** 0.3
# −0.15 4/7# −1.4 ± 0.66 3/7# −0.07 ± .02 4/7# −0.13 ± 0.05
a 325 mg/d aspirin dose for 3 days). *, **, *** ; P < 0.05, P < 0.01, P < 0.0001 vs
f curves with reversal.
A B
DC
Figure 3 Representation of the mean ± S.E.M. of the thrombotic profiles of the blood of 5 individuals treated with vehicle control,
aspirin (325 mg/day for 3 days), aspirin + PRT060128 (2.5 μM spiked in vitro), eptifibatide (0.5 and 2.4 μM) after 150 sec (A), 200 sec
(B), 300 sec (C) and 500 sec (D). Asterisks indicate cessation of blood perfusion following capillary occlusion. Two out of the 5 capillaries
occluded in the 0.5 μM eptifibatide group (**).
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IIIa) and enzymes (COX-1) in mediating thrombus sta-
bility, we first perfused untreated whole blood samples,
then switched to anti-platelet-treated samples of blood.
Perfusion of eptifibatide-treated blood blocked further
thrombus growth with no apparent destabilization of the
preformed thrombi (Figure 4A; mean slope of the trea-
ted sample of blood (second perfusion, mSAP: saline,
2.7 ± 0.3 n = 7; eptifibatide, 0.17 ± 0.22, n = 7, p < 0.05 vs
saline, n = 6). In contrast, addition of 100 μM 2-
MeSAMP caused sudden destabilization of preformed
thrombi resulting in marked dethrombosis (Figure 4A;
mSAP=−1.8 ± 0.2, n = 7, p < 0.001 vs eptifibatide; 10 μM,
mSAFP=−0.77 + 0.9 (NS)). We also determined the
effects of these inhibitors on thrombi formed from blood
from aspirin-treated individuals. Aspirin alone
(Figure 4B) induced a slow and moderate destabilization
of the thrombi (mSAFP=−1.07 ± 0.3). However, perfu-
sion of blood treated with the two inhibitors over pre-
formed thrombi induced dethrombosis (2-MeSAMP
(100 μM, mSAP=−4.1 ± 0.7; 10 μM, mSAP=−2.19 ±
0.28); eptifibatide (mSAP=−2.6 ± 0.9); n = 7, p < 0.05 vs
respective monotherapies and aspirin alone).Antithrombotic profiles of clopidogrel, aspirin and their
combinations
To determine how aspirin and clopidogrel effected
thrombus growth and thrombus stability in this model,
we evaluated the effects of chronic dosing of these drugs
on the thrombotic profiles of 20 healthy volunteers.
These drugs, taken individually or in combination, did
not affect the time for the platelets to reach firm adhe-
sion on the collagen surface. Some destabilization of
thrombi occurred following clopidogrel and aspirin
monotherapies which contributed to an overall decrease
in the maximum peak and the slope of the curve
(Figure 5A, B and Table 3). Under our experimental con-
ditions, aspirin and clopidogrel showed similar anti-
thrombotic activities in normal volunteers with aspirin
demonstrating slightly more variable inhibition than clo-
pidogrel. Four out of twenty individuals (blue asterisk)
treated with aspirin or clopidogrel did not show signifi-
cant benefit from the therapy. However, while the com-
bination of clopidogrel and aspirin did not affect the
initial growth of the thrombi on collagen (until T 2 min-
utes), it allowed for marked dethrombosis and cyclic
thrombotic process in the twenty donors (Figure 5C).
Figure 4 Effects of 2-MeSAMP and eptifibatide on preformed thrombi. Representation of the mean± S.E.M. of the thrombotic profiles
generated by perfusion of untreated sample of blood (for 210 sec) immediately followed by an additional perfusion of blood treated with either
saline, 2-MeSAMP (100 μM) or eptifibatide (2.4 μM) in (A) absence, or (B) presence of aspirin.
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ago to study platelet thrombosis in samples of non-
anticoagulated or anticoagulated blood exposed to
physiological thrombogenic surfaces under defined con-
ditions of shear (for review, see [18]). Major contribu-
tions to the field of thrombosis have been reviewed by
Sakariassen and coworkers [19,20]. These include: - the
understanding of the mechanisms of inherited clinical
disorders associated with platelet pathology (e.g., von
Willebrand disease, Glanzmann thrombasthenia, Ber-
nard Soulier Syndrome, etc.. . .), - the relative role of co-
agulation factors in thrombosis (Tissue factor,
Fibrinogen, FVII, FVIII, FIX, FXI and FXII), - the critical
role of platelet membrane glycoproteins (GP IIb-IIIa,
GPIb-IX-V and GPVI) in mediating platelet adhesion
and thrombus growth under arterial shear rates, - the
agonist activities of ADP and TxA2. Perfusion chamber
technology has also proven instructive in monitoring the
antithrombotic activity achieved by antithrombotic ther-
apies and their combination, e.g. clopidogrel plus aspirin.
Data showed that the clinical benefits achieved by thecombination of these two drugs were superior to each
drug used as monotherapy [6,17,21]. Recently published
manuscripts by Hosokawa et al. measuring perfusion
chamber flow pressure changes to evaluate the throm-
botic profiles of whole blood support the methodology
described here [22,23]. Despite the different quantifica-
tion methods, the measured effects on thrombus forma-
tion and stability were similar- specifically the activities
of aspirin alone, P2Y12 inhibitor alone, the combination
of aspirin and P2Y12 inhibitor and the GP IIb-IIIa
inhibitor.
As highlighted in this manuscript, three considerations
suggest that continuous monitoring of thrombosis at ar-
terial rates of shear would be of value to understand the
molecular mechanism regulating arterial thrombosis and
to determine the antithrombotic activity achieved in in-
dividual patients: First, the assay provides immediate,
real time evaluation of the kinetics of thrombosis, it is
easy to use, reproducible, detects and differentiates the
activity of mono and combination therapies, and can be
used as a bedside device. Second, it has become clear
A B
C
Figure 5 A), Representation of the mean± S.E.M. of the thrombotic profiles of twenty individuals successively evaluated at baseline
(B.), on clopidogrel (C.), clopidogrel + aspirin (C. + A.), then aspirin (A.) treatments (experiments carried at 1500/sec). B), Whisker graph
depicting the median fluorescence intensity (pixels)/ total area (μm2) (on y-axis) at the maximum peak for each treatment condition, showing the
maximum and minimum values for n = 20 subjects, as well as 25% and 75% confidence intervals. C), Individual variations in fluorescence intensity
between baseline and the various treatments.
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from experiments in animals such as those using the
Folts model that platelet factors exist that mediate or in-
hibit thrombus stability. Our data obtained in blood
from healthy volunteers confirmed the fact the clinical
efficacy of the state-of-the art antiplatelet therapy (clopi-
dogrel + aspirin) utilized in the management of post-
atherothrombotic events certainly stems from aTable 3 Characteristics of the thrombotic profile of healthy su
Parameters Baseline
Max. Peak (pixels/μm2) M ± sem median 800 ± 51 797
Time to the peak (sec) M ± sem Median 240 240
Slope before peak M ± sem Median 4.3 ± 0.3 4.3
Slope after peak M ± sem median NA
Thrombus volume (μm3/μm2) M ± sem 37 ± 5.2
Healthy subjects were evaluated at baseline, following clopidogrel (75 mg/d for 14
7 days), then aspirin (325 mg/day for 14 days) therapies. M (mean), *, **, *** ; P < 0.0
P < 0.001 vs aspirin. Blood perfusion of 250 seconds; # indicates number of curves w
morphometry analysis of cross-sections cut perpendicularly to the blood flow at 8 msynergism in destabilization activities of the two drugs
[11,12,24]. They also suggested that high levels of inhib-
ition of the P2Y12 receptor may be sufficient to provide
substantial benefits in agreement with others [17,25].
The effect of eptifibatide related on the other hand, to
the inhibition of thrombus growth. This is particularly
important as we found that 0.5 μM eptifibatide (the
plasma concentration achieved during the IMPACT-IIbjects
Clopidogrel Clopidogrel +ASA ASA
516 ± 48** 526 263 ± 53***,†, { 243 484 ± 67* 460
239 ± 1 240 203 ± 12*, † 208 234 ± 6 240
2.7 ± 0.2** 2.7 1.6 ± 0.2***,†, { 1.6 2.7 ± 0.4 2.65
1 out of 8# −0.18 5 out of 8# −1.2 ± 0.8 2 out of 8# −0.5 ± 0.4
25.8 ± 3.7 5.4 ± 0.5 22.1 ± 4.8
days), clopidogrel (75 mg/d for an additional 7 days) + aspirin (325 mg/d for
5, P < 0.01, P < 0.0001 vs baseline, respectively. †, P < 0.05 vs clopidogrel. {,
ith reversal. Thrombus volume (μm3/μm2) was evaluated by computer assisted
m from the proximal end of the capillary.
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efits[26]) only delayed the growth of the thrombus, but
could not prevent occlusion of the collagen-coated capil-
lary upon prolonged perfusion (Figure 3). Third, emer-
ging data suggest that the antithrombotic response to
aspirin and clopidogrel is variable, possibly including
non-responders [27,28]. Three out of 20 healthy indivi-
duals did not benefit from either aspirin or clopidogrel
treatments, suggesting non-responsiveness. Interestingly
however, all individuals showed robust inhibition while
on combination regimen, indicating that the mechan-
isms targeted (COX-1 or P2Y12) while inhibited, could
not account for antithrombotic activity without con-
comitant inhibition of the other signaling pathway.
Limitations
While this methodology for the evaluation of anti-
platelet therapies has obvious benefits, there are also
limitations that warrant discussion: i) use of a single
purified protein surface rather than damaged endothelial
cells- the choice of collagen can affect the thrombotic
process therefore careful standardization of the collagen
preparation (or protein of choice) is required ii) use of
anticoagulant- a method for evaluation in absence of
anticoagulant at low and high shear would facilitate the
study of existing therapies on both fibrin formation and
platelet deposition simultaneously. Based on the opti-
mized conditions used in this study (high shear, and Fac-
tor Xa anticoagulant), our results relate to platelet rich
thrombi only.
Conclusions
Coupling the real time feature of intravital technology
with perfusion chamber has been proposed by the group
of McIntire almost 20 years ago [4]. This concept was
based on the simple idea that real time monitoring of
perfusion chambers would circumvent the limitations of
light transmittance aggregometry and other point of care
devices which either: i) do not offer continuous monitor-
ing of the kinetics of arterial thrombosis, ii) interrogate
only one platelet signaling pathway at a time and there-
fore cannot provide reliable monitoring of combination
therapies. The system described herein offers a relatively
simple and reproducible technology that can be utilized
to: i) characterize the mechanism of action and activity of
antiplatelet or anticoagulant agents ii) possibly tailor pa-
tient therapy [29], iii) identify novel antiplatelet targets.
Methods
Real time perfusion chamber assay
Blood was collected from the antecubital vein of subjects
who gave written informed consent to the protocol (Ap-
proval was obtained from Western Institutional Review
Board or the California Pacific Medical Centre HumanSubjects Committee) via butterfly 19 G on syringes con-
taining 5 μM (final concentration) of the factor Xa in-
hibitor C921-78, a concentration sufficient to block any
FXa activity [30].
Platelets were labeled in whole blood by adding an ali-
quot of Rhodamine 6 G (final concentration, 1.25 μg/ml).
To visualize platelet deposition through the microscope,
the dye was excited with light from a high-power light
emitting diode with a spectral maximum at 530 nm and
a spectral half width of 35 nm (Luxeon V, Lumileds
Lighting, San Jose, CA). Excitation and emission lights
were filtered with a set of fluorescence filters (31002,
Chroma Technologies, Rockingham, VT). A microscope
objective imaged an area of 360 x 270 μm on the internal
wall of the capillary onto a Sony XCD X-710 digital cam-
era (resulting magnification ca. 13 x). Images were
recorded at a frequency of 1 Hz. Blood flow was estab-
lished by a syringe pump withdrawing blood through the
capillary (Harvard Apparatus, Holliston, MA). A per-
sonal computer with custom software was used to con-
trol the camera and the syringe pump, and to display and
record images and experimental conditions.
Unless otherwise specified, whole blood was perfused
through the capillary at 1000 or 1500/sec for a period of
5 minutes according to the following equation:
γ= 1.03x6Q/ab2, where γ= shear rate; Q= volumetric
flow rate (ml/60); b = height (cm); a width (cm).
Antithrombotic activities of antiplatelet agents
Eptifibatide (added in vitro at 0.125 to 2.4 μM) and 2-
MeSAMP (a direct P2Y12 antagonist added in vitro at 10
and 100 μM, a concentration that fully antagonizes
P2Y12 [12]) effects were tested in absence or presence of
aspirin (325 mg QD for 3 days) at 1000/sec. Qualitative
and quantitative changes in thrombotic profiles of 5
individuals treated with vehicle control, aspirin, aspirin +
PRT060128 (2.5 μM, [31]) or eptifibatide (0.5 and
2.4 μM) were also assessed over a 500 second perfusion
period.
In a second set of experiments, we asked whether
addition of inhibitors of the receptors for fibrinogen (GP
IIb-IIIa) or ADP (P2Y12) to preformed thrombi could in-
duce dethrombosis. Untreated blood samples were per-
fused at 1500/sec through the chamber for 210 seconds,
followed by blood treated with saline, 2.4 μM eptifiba-
tide, or 2-MeSAMP (10, 100 μM) for 100 seconds. Simi-
lar design was applied to the blood of normal volunteers
who had been taking aspirin (325 mg/d) for 3 consecu-
tive days.
Monitoring the antithrombotic activities of clopidogrel,
aspirin and clopidogrel + aspirin in humans
Antithrombotic effects were evaluated in a sequential
study at the California Pacific Medical Centre (CPMC,
Stephens et al. Thrombosis Journal 2012, 10:11 Page 10 of 11
http://www.thrombosisjournal.com/content/10/1/11San Francisco, CA). Twenty individuals were evaluated
before antithrombotic therapy, 2 weeks after a daily regi-
men of clopidogrel (75 mg/d), 1 week after a dual clopi-
dogrel (75 mg/d) + aspirin (325 mg/d) therapy, and
finally 2 weeks off clopidogrel therapy while continuing
on aspirin regimen (325 mg/d).
Statistical analysis
Statistics were performed with Graph Pad Prism v4.03
and numerical data are presented as mean ± S.E.M. The
significance between two data sets was tested using
paired t-test for the CPMC study, and unpaired t-test for
all other in vitro studies. p < 0.05 was considered to be
statistically significant.
Additional files
Additional file 1: Figure S1. A), Illustration of the real time thrombosis
profiler. (1), Harvard Apparatus mono-syringe pump; (2), thermostat
controller; (3), on/off switches of the pump, lamp source and
thermostatic holder; (4–6), control knobs for 3-axis sample translation
stage; (7), holding stage; (8), 20X Nikon microscope objective; The Sony
XCD-X710 camera is mounted on top of the objective (not shown) B),
Holding stage. The glass capillary is placed between 2 sets of springs, the
holding stage slide on two steel bars to its position under the objective
of the microscope. This reduces the need for X, Y, and Z focusing. C),
Left, en face representative picture of thrombotic deposits formed at the
proximal part of the capillary. Thrombi were rinsed, fixed and stained
with toluidine blue following perfusion of untreated whole blood (1000/
sec, 5 minutes perfusion) through the collagen coated perfusion
chamber as previously described. Right, semithin cross-section of epon-
embedded thrombotic deposits cut perpendicular to the direction of the
blood flow at the proximal part of the capillary. D), Time course of the
labeling of platelets with rhodamine 6 G as determined by FACS analysis.
T0 corresponds to endogenous fluorescence intensity of the platelets
prior to incubation with R6G. E), Computer. F), Schematic of the
parameters recorded for each curve, maximum peak (P), time to reach
the peak (T), slope before the peak (sBP), and slope after the peak (sAP).
Different antithrombotic profiles are presented as an example.
Additional file 2: Video S1. Three-dimensional reconstruction of the
thrombotic process (untreated sample of blood) triggered by type III
collagen at 1500/sec. Relative increase in platelet accumulation is
indicated by progression in color from red to white peaks.
Additional file 3: Video S2. Full P2Y12 antagonism induced
dethrombosis.
Additional file 4: Video S3. Thrombotic process triggered by type III
collagen at 1500/sec in an individual treated with aspirin (325 mg/d for
3 days and 10 μM 2-MeSAMP).
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